Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 414207, 14 pages
http://dx.doi.org/10.1155/2015/414207
Research Article

Pegylated Interferon- Modulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar Rat

1Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, P.O. Box 7607, Al Abdeyah, Makkah, Saudi Arabia
2Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut 6515, Egypt

Received 27 February 2015; Revised 30 May 2015; Accepted 3 June 2015

Academic Editor: Limin Chen

Copyright © 2015 Bassem Refaat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. M. Averhoff, N. Glass, and D. Holtzman, “Global burden of hepatitis C: considerations for healthcare providers in the United States,” Clinical Infectious Diseases, vol. 55, supplement 1, pp. S10–S15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. M. D. Sadler and S. S. Lee, “Revolution in hepatitis C antiviral therapy,” British Medical Bulletin, vol. 113, pp. 31–44, 2015. View at Publisher · View at Google Scholar
  3. B. Refaat, A. M. Ashshi, A. G. El-Shemi, and E. Azhar, “Activins and follistatin in chronic hepatitis C and its treatment with pegylated-interferon-α based therapy,” Mediators of Inflammation, vol. 2015, Article ID 287640, 16 pages, 2015. View at Publisher · View at Google Scholar
  4. M. Stepanova and Z. M. Younossi, “Interferon-free regimens for chronic Hepatitis C: barriers due to treatment candidacy and insurance coverage,” Digestive Diseases and Sciences, 2015. View at Publisher · View at Google Scholar
  5. M. Hellard and N. Scott, “The changing landscape of hepatitis C treatment-not ‘can we cure?’ but ‘who should we cure first?’ Is this an ethical approach?” Addiction, vol. 110, no. 6, pp. 984–985, 2015. View at Publisher · View at Google Scholar
  6. M. Colombo, “Interferon-free therapy for hepatitis C: the hurdles amid a golden era,” Digestive and Liver Disease, 2015. View at Publisher · View at Google Scholar
  7. S. Bansal, A. K. Singal, B. M. McGuire, and B. S. Anand, “Impact of all oral anti-hepatitis C virus therapy: a meta-analysis,” World Journal of Hepatology, vol. 7, no. 5, pp. 806–813, 2015. View at Publisher · View at Google Scholar
  8. J. D. Farrar and K. M. Murphy, “Type I interferons and T helper development,” Immunology Today, vol. 21, no. 10, pp. 484–489, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Jimenez-Sousa, R. Almansa, C. de La Fuente et al., “Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin,” European Cytokine Network, vol. 21, no. 2, pp. 84–91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Moser and K. M. Murphy, “Dendritic cell regulation of TH1-TH2 development,” Nature Immunology, vol. 1, no. 3, pp. 199–205, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Fallahi, C. Ferri, S. M. Ferrari, A. Corrado, D. Sansonno, and A. Antonelli, “Cytokines and HCV-related disorders,” Clinical and Developmental Immunology, vol. 2012, Article ID 468107, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Tilg, “New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine,” Gastroenterology, vol. 112, no. 3, pp. 1017–1021, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Ueyama, M. Nakagawa, N. Sakamoto et al., “Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin,” Antiviral Therapy, vol. 16, no. 7, pp. 1081–1091, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E.-J. Pavón-Castillero, P. Muñoz-de-Rueda, R. López-Segura et al., “Importance of IL-10 and IL-6 during chronic hepatitis c genotype-1 treatment and their relation with IL28B,” Cytokine, vol. 61, no. 2, pp. 595–601, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. B. A. Refaat, A. O. Bahathiq, S. Sockanathan, R. L. Stewart, M. Wells, and W. L. Ledger, “Production and localization of activins and activin type IIA and IIB receptors by the human endosalpinx,” Reproduction, vol. 128, no. 2, pp. 249–255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Itoh and P. ten Dijke, “Negative regulation of TGF-β receptor/Smad signal transduction,” Current Opinion in Cell Biology, vol. 19, no. 2, pp. 176–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Weiss and L. Attisano, “The TGFbeta superfamily signaling pathway,” Wiley Interdisciplinary Reviews: Developmental Biology, vol. 2, no. 1, pp. 47–63, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Rodgarkia-Dara, S. Vejda, N. Erlach et al., “The activin axis in liver biology and disease,” Mutation Research, vol. 613, no. 2-3, pp. 123–137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Werner and C. Alzheimer, “Roles of activin in tissue repair, fibrosis, and inflammatory disease,” Cytokine and Growth Factor Reviews, vol. 17, no. 3, pp. 157–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Patella, D. J. Phillips, D. M. de Kretser, L. W. Evans, N. P. Groome, and W. Sievert, “Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis,” Journal of Hepatology, vol. 34, no. 4, pp. 576–583, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Y. Elsammak, G. M. Amin, G. M. Khalil, W. S. Ragab, and M. M. Abaza, “Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis,” Clinical Biochemistry, vol. 39, no. 6, pp. 623–629, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Refaat, A. Ashshi, A. El-Shemi, and A. AlZanbagi, “Effects of chronic hepatitis C genotype 1 and 4 on serum activins and follistatin in treatment naïve patients and their correlations with interleukin-6, tumour necrosis factor-α, viral load and liver damage,” Clinical and Experimental Medicine, 2014. View at Publisher · View at Google Scholar
  23. B. Refaat, A. G. El-Shemi, A. M. Ashshi, and A. Alzanbagi, “Serum activins and follistatin during the treatment of chronic hepatitis c genotypes 1 and 4 and their correlations with viral load and liver enzymes: a preliminary report,” Gastroenterology Research and Practice, vol. 2014, Article ID 628683, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Prakash, E. Tuckerman, S. Laird, B. Ola, T. C. Li, and W. L. Ledger, “A preliminary study comparing the endometrial expression of inhibin, activin and follistatin in women with a history of implantation failure after IVF treatment and a control group,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 115, no. 4, pp. 532–537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Refaat, T. H. Ashour, and A. G. El-Shemi, “Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat,” International Journal of Clinical and Experimental Medicine, vol. 7, pp. 2667–2676, 2014. View at Google Scholar
  27. Y.-Q. Zhang, M. Kanzaki, H. Mashima, T. Mine, and I. Kojima, “Characterization of the activin receptor in cultured rat hepatocytes,” Hepatology, vol. 24, no. 2, pp. 446–450, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Clotman and F. P. Lemaigre, “Control of hepatic differentiation by activin/TGFβ signaling,” Cell Cycle, vol. 5, no. 2, pp. 168–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Takamura, K. Tsuchida, H. Miyake, S. Tashiro, and H. Sugino, “Activin and activin receptor expression changes in liver regeneration in rat,” Journal of Surgical Research, vol. 126, no. 1, pp. 3–11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. R. H. Schwall, K. Robbins, P. Jardieu, L. Chang, C. Lai, and T. G. Terrell, “Activin induces cell death in hepatocytes in vivo and in vitro,” Hepatology, vol. 18, no. 2, pp. 347–356, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Ho, C. de Guise, C. Kim, S. Lemay, X.-F. Wang, and J.-J. Lebrun, “Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1,” Cellular Signalling, vol. 16, no. 6, pp. 693–701, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Chen, W. Zhang, H.-F. Liang et al., “Activin A induces growth arrest through a SMAD-dependent pathway in hepatic progenitor cells,” Cell Communication and Signaling, vol. 12, no. 1, article 18, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Takamura, K. Tsuchida, H. Miyake, S. Tashiro, and H. Sugino, “Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats,” Hepato-Gastroenterology, vol. 52, no. 61, pp. 60–66, 2005. View at Google Scholar · View at Scopus
  34. E. J. Gold, X. Zhang, A. M. Wheatley et al., “βA- and βC-activin, follistatin, activin receptor mRNA and βC-activin peptide expression during rat liver regeneration,” Journal of Molecular Endocrinology, vol. 34, no. 2, pp. 505–515, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Fujii, M. Ishikawa, M. Iuchi, and S. Tashiro, “Effect of follistatin on rat liver regeneration and tumor growth after portal occlusion,” Hepato-Gastroenterology, vol. 52, no. 63, pp. 833–838, 2005. View at Google Scholar · View at Scopus
  36. E. J. Gold, R. J. B. Francis, A. Zimmermann et al., “Changes in activin and activin receptor subunit expression in rat liver during the development of CCl4-induced cirrhosis,” Molecular and Cellular Endocrinology, vol. 201, no. 1-2, pp. 143–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Yndestad, J. W. Haukeland, T. B. Dahl et al., “A complex role of activin A in non-alcoholic fatty liver disease,” The American Journal of Gastroenterology, vol. 104, no. 9, pp. 2196–2205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. R. D. Hughes and L. W. Evans, “Activin A and follistatin in acute liver failure,” European Journal of Gastroenterology and Hepatology, vol. 15, no. 2, pp. 127–131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Yndestad, J. W. Haukeland, T. B. Dahl, B. Halvorsen, and P. Aukrust, “Activin A in nonalcoholic fatty liver disease,” Vitamins and Hormones, vol. 85, pp. 323–342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. P. Ofstad, L. Gullestad, E. Orvik et al., “Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study,” Cardiovascular Diabetology, vol. 12, no. 1, article 126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. O. Yoshino, G. Izumi, J. Shi et al., “Activin-A is induced by interleukin-1β and tumor necrosis factor-α and enhances the mRNA expression of interleukin-6 and protease-activated receptor-2 and proliferation of stromal cells from endometrioma,” Fertility and Sterility, vol. 96, no. 1, pp. 118–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Tsumoto, D. Ejima, K. Nagase, and T. Arakawa, “Arginine improves protein elution in hydrophobic interaction chromatography. The cases of human interleukin-6 and activin-A,” Journal of Chromatography A, vol. 1154, no. 1-2, pp. 81–86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Weng, P. R. Mertens, A. M. Gressner, and S. Dooley, “IFN-γ abrogates profibrogenic TGF-β signaling in liver by targeting expression of inhibitory and receptor Smads,” Journal of Hepatology, vol. 46, no. 2, pp. 295–303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Q. Liu, D. H. Hu, Z. F. Zhang et al., “Effects of interferon-gamma on the transforming growth factor beta/Smad pathway in keloid-derived fibroblasts,” Zhonghua Shao Shang Za Zhi, vol. 25, pp. 454–459, 2009. View at Google Scholar
  45. H.-Y. Rao, L. Wei, J.-H. Wang et al., “Inhibitory effect of human interferon-beta-1a on activated rat and human hepatic stellate cells,” Journal of Gastroenterology and Hepatology, vol. 25, no. 11, pp. 1777–1784, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Abe, Y. Shintani, Y. Eto et al., “Interleukin-1 β enhances and interferon-γ suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts,” Clinical and Experimental Immunology, vol. 126, no. 1, pp. 64–68, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. K. S. Famulski, B. Sis, L. Billesberger, and P. F. Halloran, “Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm,” The American Journal of Transplantation, vol. 8, no. 3, pp. 547–556, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. W.-H. Lee, M.-H. Chung, Y.-H. Tsai, J.-L. Chang, and H.-M. Huang, “Interferon-γ suppresses activin A/NF-E2 induction of erythroid gene expression through the NF-κB/c-Jun pathway,” American Journal of Physiology—Cell Physiology, vol. 306, no. 4, pp. C407–C414, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Sierra-Filardi, A. Puig-Kröger, F. J. Blanco et al., “Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers,” Blood, vol. 117, no. 19, pp. 5092–5101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Hammond, S. Lee, M. W. Watson et al., “Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus,” Cellular Immunology, vol. 264, no. 2, pp. 150–155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. K. L. Jones, D. M. D. Kretser, S. Patella, and D. J. Phillips, “Activin A and follistatin in systemic inflammation,” Molecular and Cellular Endocrinology, vol. 225, no. 1-2, pp. 119–125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. K. L. Jones, D. M. de Kretser, I. J. Clarke, J.-P. Y. Scheerlinck, and D. J. Phillips, “Characterisation of the rapid release of activin A following acute lipopolysaccharide challenge in the ewe,” Journal of Endocrinology, vol. 182, no. 1, pp. 69–80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Ahlenstiel, B. Edlich, L. J. Hogdal et al., “Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C,” Gastroenterology, vol. 141, no. 4, pp. 1231–1239.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Semitekolou, T. Alissafi, M. Aggelakopoulou et al., “Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease,” Journal of Experimental Medicine, vol. 206, no. 8, pp. 1769–1785, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. T. N. Q. Pham, D. M. H. Lin, P. M. Mulrooney-Cousins et al., “Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment,” Journal of Medical Virology, vol. 85, no. 3, pp. 441–448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Refaat, S. Amer, B. Ola, N. Chapman, and W. Ledger, “The expression of activin-betaA- and -betaB-subunits, follistatin, and activin type II receptors in fallopian tubes bearing an ectopic pregnancy,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 1, pp. 293–299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. A. L. Blount, J. M. Vaughan, W. W. Vale, and L. M. Bilezikjian, “A smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene,” The Journal of Biological Chemistry, vol. 283, no. 11, pp. 7016–7026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. K. M. Wilson, A. I. Smith, and D. J. Phillips, “Stimulatory effects of lipopolysaccharide on endothelial cell activin and follistatin,” Molecular and Cellular Endocrinology, vol. 253, no. 1-2, pp. 30–35, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. J. A. Keelan, R. L. Zhou, L. W. Evans, N. P. Groome, and M. D. Mitchell, “Regulation of activin A, inhibin A, and follistatin production in human amnion and choriodecidual explants by inflammatory mediators,” Journal of the Society for Gynecologic Investigation, vol. 7, no. 5, pp. 291–296, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Lutchman, S. Danehower, B.-C. Song et al., “Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy,” Gastroenterology, vol. 132, no. 5, pp. 1757–1766, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. N. J. Stevenson, A. G. Murphy, N. M. Bourke, C. A. Keogh, J. E. Hegarty, and C. O'Farrelly, “Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV,” PLoS ONE, vol. 6, no. 11, Article ID e27866, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. A. L. Schneyer, H. A. Hall, G. Lambert-messerlian, Q. F. Wang, P. Sluss, and W. F. Crowley Jr., “Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically,” Endocrinology, vol. 137, no. 1, pp. 240–247, 1996. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Nakamura, K. Sugino, K. Titani, and H. Sugino, “Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells,” The Journal of Biological Chemistry, vol. 266, no. 29, pp. 19432–19437, 1991. View at Google Scholar · View at Scopus